The tuberculosis (TB) treatment success rate for newly treated cases in China stood at 94 units in 2023. This rate has demonstrated remarkable stability over recent years, maintaining the same value from 2018 through the forecast period to 2028. The year-on-year variation between 2022 and 2023, as well as over the last two years, shows no change. The five-year compound annual growth rate (CAGR) remains at 0%, indicating no average variation per year over the last five years. As such, the forecasted growth rate over the next five years also stands at 0%.
Future trends to watch for include the potential impact of new TB medication developments and public health initiatives. Monitoring these factors will be crucial to determine if they can enhance treatment success rates beyond the current plateau by 2028.
